Precordior in brief

Cardiovascular diseases (CVD) are the most common cause of death in the world accounting for loss of 17.9m lives per year. In Europe CVD accounts annually for 3.9m fatalities and $233b in costs. In the USA, CVD causes 840,000 deaths and $555b in costs every year — and this cost is expected to double by 2035. Early identification and treatment of CVD such as atrial fibrillation (AFib), heart failure (HF), and coronary artery disease (CAD) would help prevent strokes and heart attacks, and improve outcomes for individuals and society. Precordior's technology allows easy, accurate monitoring of the heart to identify serious symptoms.

Precordior's history

In 2012, a forerunner team of Finnish researchers set out to explore micro-motions of the chest and what these can tell about the condition of your heart. As it turned out, quite a lot.

The saga of Precordior dates back to 2011, when Tero Koivisto, a researcher at the University of Turku, and Tuomas Valtonen, a specialist in public research funding, visited companies throughout Finland to explain why personal health technology will be the next big thing on the global market. This led to the first research project in 2012, Whispers-Start, resulting in the group's earliest inventions and patent applications. During 2012—2016 the research group received more than $6m in funding, research efforts driven by Tero Koivisto and Dr. Mikko Pänkäälä, the third founder of Precordior.

Precordior today

Precordior continues the nearly decade-long scientific work on ground-breaking new methods for cardiac analysis. We have started commercial sales and marketing, are engaged in European research projects and are rapidly growing.

Today CardioSignal by Precordior®, our CE IIa certified smartphone solution for detecting atrial fibrillation, is widely available in Europe via Google Play and App Store. Thanks to our app-cloud based technology, any smartphone user can detect atrial fibrillation at home without purchasing any additional devices. This year we expanded sales from our home market Finland to the United Kingdom, Ireland, Germany, France, Spain, Italy, Switzerland, Austria and Sweden. Eventually sales will cover most of Europe.

In 2021 we are planning to expand sales to the USA, and further to other global regions within the next 1-2 years.


We have grown from four founders and two investors into a team of 20 experts, backed by a group of nine investors. We are currently participating in three European funded projects – Applause, Moore4Medical and CardioSignal – the latter of which is our company's EIC SME2 funded project worth $3.1m.

As an ISO 13485 certified company, quality is in the essence of all of our activities. Our entire staff follows and abides by rigid rules and procedures to ensure the quality and reliability of our products. We take pride in running a well organised business and providing quality to our customers.

We are proud to help empower people globally to reliably monitor their health and improve quality of life.

Precordior tomorrow

Our first commercial solution detects AFib via the smartphone with more than 95% reliability. Next we shall extend detection capabilities to other dangerous heart conditions and enter new market areas beyond the EU. We will also develop advanced solutions for continuous and long-term cardiac monitoring.

Winning the EIC SME2 grant from the European Commission represents a major milestone in our company's path towards the global markets. On one hand, the grant is only awarded to the top 4% of applying European SMEs, and we are proud to join this highly selective group of SMEs expected to move the future market. On the other hand, the $2.2m grant now enables Precordior to aim beyond atrial fibrillation and at detecting other often unnoticed but deadly cardiac disorders: heart failure (HF) and coronary artery disease (CAD). After the SME2 project in 2022, we plan to launch our HF and CAD product suite to the market.

Precordior Ltd. is supported by the European Union.
Project no. 954566 CardioSignal
Duration: 2020–2022
Topic: EIC-SMEInst-2018-2020
Type of action: SME-2b.